|
 U.S. District Judge Denise Cote in Manhattan found no plausible
allegations that Pfizer had a duty to disclose that Chantix was
contaminated by a type of carcinogen known as a nitrosamine, or was
unfit to help consumers quit smoking. She also found no proof that
Pfizer's labels were misleading.
Plaintiffs Roslyn Harris, of Jersey City, New Jersey, and Mary
Allen, of Warrensburg, New York, claimed that Chantix was
"worthless" because of the contamination, and that they would not
have bought the drug had they known about it.
A lawyer for the plaintiffs did not immediately respond to requests
for comment.
Pfizer said it was pleased with the decision. "We continue to stand
behind the safety and efficacy of Chantix, which has helped millions
of Americans quit cigarette smoking," it said in a statement.
[to top of second column] |
 Cote said that because Pfizer offered full
rebates for unused Chantix, the lawsuit sought
damages only for tablets that the plaintiffs
consumed.
Pfizer began recalling Chantix last July, and
extended the recall nationwide in mid-September.
The New York-based company won U.S. Food and
Drug Administration approval in 2006 for Chantix
to help adults quit smoking. Sales dropped 57%
last year, reflecting the recall, Pfizer said
this month.
The case is Harris et al v Pfizer Inc, U.S.
District Court, Southern District of New York,
No. 21-06789.
(Reporting by Jonathan Stempel in New York;
Editing by Stephen Coates)
[© 2022 Thomson Reuters. All rights
reserved.] This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
